Nanjing, China – GemPharmatech has been named one of the “Top 100 Brands of Chinese Life Science Service Enterprises” for 2024 by Healthcare Executive, a leading voice in China’s pharmaceutical industry. The recognition highlights GemPharmatech’s growing influence as a trusted research partner in China’s rapidly advancing biotech landscape.

The award reflects the company’s continued leadership in supporting pharmaceutical innovation through its comprehensive portfolio of genetically engineered mouse models (GEMMs), Patient-Derived Xenograft (PDX) models, and preclinical research services. As China's life science ecosystem evolves toward greater global competitiveness, GemPharmatech is helping set the standard for scientific rigor, operational excellence, and international collaboration.

“Being named one of the Top 100 Life Science Service Brands is a testament to the trust our partners place in us and the value we deliver across the drug development pipeline,” said Dr. Brandy Wilkinson, CEO of GemPharmatech, LLC. “We are proud to play a role in driving forward the innovation capacity of China’s pharmaceutical sector, while also bridging global R&D efforts.”

The selection process, conducted over a three-month period, involved extensive data analysis and industry feedback. Market value, customer coverage, brand recognition, and service quality were all evaluated through a survey of R&D, production, and quality executives at 40 leading pharmaceutical companies, including Qilu Pharmaceutical and Hengrui Pharmaceutical.

The final rankings were determined based on three weighted dimensions:

· Brand recognition (50%)

· Cost-effectiveness of collaboration (30%)

· Service satisfaction (20%)

As the global pharmaceutical industry becomes increasingly integrated, GemPharmatech continues to expand its capabilities and global footprint—providing reliable, scalable, and scientifically validated solutions to support drug discovery and development worldwide.

This recognition reinforces the company’s commitment to building a robust, collaborative life science innovation ecosystem in China and beyond.